Compare DigitalOcean Holdings Inc (DOCN) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DigitalOcean Holdings Inc vs Merck & Co., Inc. — how do they compare? DigitalOcean Holdings Inc trades at $129.6 (market cap $14.57B), while Merck & Co., Inc. trades at $144.69 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 24.1× DigitalOcean Holdings Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while DigitalOcean Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold DigitalOcean Holdings Inc for 43 Days and Merck & Co., Inc. for 98 Days on average.
| DOCN | MRK | |
|---|---|---|
Market Cap | $14.57B | $351.28B |
Volume | 2,261,786 | 7,969,665 |
Sector | Technology | Health |
52-Week High | $181.29 | $156.43 |
52-Week Low | $37.30 | $82.49 |
Typical Hold Time | 43 Days | 98 Days |
Enterprise Value | $15.33B | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DigitalOcean trades at $127.28, down 2.89% today, with strong fundamentals including 29% revenue growth and consistent earnings beats. The company shows robust profitability with 57.22% gross margins and 23.27% net income margin, though valuation metrics remain elevated with P/E of 56.32. Recent AI-focused product launches and $725 million equipment financing facility support growth initiatives. Technical indicators show mixed signals with bullish oscillators but bearish moving averages, trading near key support at $126.
Outlook remains positive with analyst consensus target of $172.73 (35.7% upside) and 68% buy ratings. Key opportunities include AI-driven revenue growth and expanding cloud market share, while risks include high valuation, negative shareholder equity, and competitive pressure from larger cloud providers. The stock offers growth potential but requires careful monitoring of execution and market conditions.
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DigitalOcean Holdings Inc
DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. The group has a business presence in North America, Europe, Asia and other countries.
Read more on DOCN →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
